Developer docs
API playgroundTry for free, no card

Search company profiles

WPD Pharmaceuticals

Full company profile

uuid000336i

Namestring
WPD Pharmaceuticals
Legal namestring
WPD Pharmaceuticals Inc.
Company typeenum
Public
Founded yearint
2008
Descriptiontext

WPD Pharmaceuticals Inc. (CSE: WBIO, FSE: 8SV1) is a publicly traded Canadian holding company headquartered in Vancouver that, as of late 2022, has no active business operations. The entity originated as Sparrow Ventures Corp. (IPO 2008), was later renamed Westcot Ventures Corp., and in December 2019 completed a reverse takeover of WPD Pharmaceuticals Sp. z o.o., a Poland-based biotechnology R&D company focused on oncology drug development. Following a November 2022 restructuring, WPD Pharmaceuticals Inc. lost control of the Polish subsidiary and now retains only an approximately 7% equity stake; the Polish entity continues to develop drug candidates including Berubicin (recurrent glioblastoma multiforme, Phase 1B/2), Annamycin in liposomal form (acute myeloid leukemia and soft tissue sarcoma lung metastases, Phase 1B/2), WP1066 (STAT3 inhibitor, FDA IND-approved in pediatric brain cancer), and WP1122 (glycolysis inhibition, including SARS-CoV-2 work), all licensed from Wake Forest University Health Sciences. Historical revenue mechanics centered on licensing royalties and government grant funding (notably ~C$7.4M for Berubicin, ~C$6.7M for Annamycin, and ~US$6.3M for liposomal Annamycin AML development), with cumulative drug-development spend exceeding US$100M as of February 2020; the parent entity itself currently generates no revenue.

Short descriptiontext

WPD Pharmaceuticals Inc. (CSE: WBIO, FSE: 8SV1) is a publicly traded Canadian holding company with no active operations, holding approximately 7% of its former Polish oncology R&D subsidiary, WPD Pharmaceuticals Sp. z o.o.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersWarsaw, Poland
HQ citystring
Warsaw
HQ countrystring
Poland
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
oncology drug development, biopharmaceutical research, clinical trials oncology, small molecule therapeutics, biologics development
Industry2 codes
PRIMARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Oncology Pharmaceuticals
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing Royalties
TypeLicensing Royalties
Description

The company generates no active revenue currently. WPD Pharmaceuticals Inc. (CSE: WBIO) has no active business operations. The company's sole asset is shares (approximately 7%) in its former subsidiary WPD Pharmaceuticals Sp. z o.o., a biotechnology R&D company in Poland that focuses on oncology drug development.

wpdpharmaceuticals.com
2Grant Funding
TypeLicensing Royalties
Description

The company has historically received government grants for drug development including C$7.4 million grant for Berubicin development and $6.3M grant for liposomal Annamycin development for AML treatment.

wpdpharmaceuticals.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

WPD Pharmaceuticals Inc. is a publicly traded biotechnology company focused on oncology research and development of medicinal products involving biological compounds and small molecules. Its pipeline includes licensed drug candidates such as Berubicin (for recurrent glioblastoma multiforme), Annamycin (for AML and soft tissue sarcoma lung metastases), WP1066 (a STAT3 inhibitor), and WP1122 (a glycolysis inhibitor). The company currently has no active business operations and holds approximately 7% of its former Polish subsidiary, WPD Pharmaceuticals Sp. z o.o.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • Phase 1B/2 clinical trials ongoing for Berubicin in recurrent glioblastoma multiforme
+4 more records
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2022-05-16
Description

WPD Pharmaceuticals signed an annex to its license agreement with Wake Forest University Health Sciences in May 2022. The company holds exclusive sublicense rights for Berubicin, Annamycin, WP1066, and WP1122 drug candidates. Berubicin sublicense rights were secured in perpetuity in February 2022.

2EuroNanoMed
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-03-07
Description

WPD Pharmaceuticals signed a consortium agreement with EuroNanoMed in March 2022 as part of an international research consortium.

wpdpharmaceuticals.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2021-03-30
Description

WPD Pharmaceuticals entered into an amended and restated sublicense agreement with Moleculin Biotech in January 2022, following an initial agreement in March 2021. The agreement covers WP1066, WP1122, and Annamycin drug candidates.

Strategic tierMinorTypeImplementation/ SI/ Consulting PartnerAnnounced on2021-01-14
Description

WPD Pharmaceuticals contracted Clinigen Clinical Supplies Management to perform QP (Qualified Person) certification of Berubicin for clinical trial authorization.

Strategic tierCoreTypeImplementation/ SI/ Consulting PartnerAnnounced on2020-09-09
Description

WPD Pharmaceuticals engaged Worldwide Clinical Trials as a CRO (Contract Research Organization) for Phase 2 Berubicin trials in September 2020, with additional support engaged in February 2021.

Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2020-03-24
Description

WPD Pharmaceuticals partnered with CNS Pharmaceuticals on drug development, including clinical trials for Berubicin in Poland. The companies identified leading Polish medical institutions for Berubicin Phase 2 clinical trial and received positive opinion from the Polish Central Ethics Committee.

Recent move9 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Co-development partner on Annamycin, WP1066, and WP1122 via amended and restated sublicense agreement. Highly comparable as a small-cap oncology biotech advancing the same drug candidates that originally underpinned WPD's pipeline.

TypeDirect peer
Description

Partner advancing Berubicin Phase 1B/2 trials for recurrent glioblastoma multiforme, with Polish clinical sites jointly identified. Directly comparable as a small-cap oncology biotech focused on the same lead asset.

TypeDirect peer
Description

Small-cap oncology biotech with lead asset paxalisib in glioblastoma. Comparable therapeutic focus (GBM, high unmet need) and similar company stage/size profile to the operating business previously housed in WPD's subsidiary.

TypeDirect peer
Description

Formed via merger with Kintara Therapeutics; focused on novel approaches to glioblastoma and other cancers. Comparable as a micro-cap oncology biotech targeting similar indications with similar regulatory/clinical risk profile.

TypeDirect peer
Description

Clinical-stage biopharma developing cell and gene therapies for oncology and rare diseases. Comparable as a small-cap public biotech with limited operating cash flow and ongoing capital-raising needs.

TypeDirect peer
Description

Clinical-stage oncology biotech developing therapeutics for KRAS-mutated cancers. Comparable in size, stage, and public small-cap oncology profile to the type of business historically operated by WPD's Polish subsidiary.

TypeDirect peer
Description

Clinical-stage biopharma developing novel oncology therapeutics targeting the p53 pathway. Comparable as a small-cap public oncology biotech with similar cash burn and dependency on clinical milestones for valuation.

TypeRegional player
Description

Canada-based clinical-stage biopharmaceutical company developing small-molecule drug candidates. Comparable as a domestic (Canadian) small-cap biotech with similar listing profile and life-sciences focus.

TypeBroad incumbent
Description

Global pharmaceutical incumbent with extensive oncology franchise including GBM treatments. Relevant as a broad incumbent that competes for the same oncology indications WPD's former subsidiary targets and that could potentially acquire/license comparable assets.

10Bristol-Myers Squibb
TypeBroad incumbent
Description

Large-cap global pharma with a deep oncology and hematology portfolio. Provides broad incumbent context for the oncology indications WPD's former subsidiary was pursuing, and represents a plausible strategic acquirer profile.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

WPD Pharmaceuticals

Oncology Pharmaceuticalswpdpharmaceuticals.com

WPD Pharmaceuticals Inc. (CSE: WBIO, FSE: 8SV1) is a publicly traded Canadian holding company with no active operations, holding approximately 7% of its former Polish oncology R&D subsidiary, WPD Pharmaceuticals Sp. z o.o.

What WPD Pharmaceuticals does

WPD Pharmaceuticals Inc. (CSE: WBIO, FSE: 8SV1) is a publicly traded Canadian holding company headquartered in Vancouver that, as of late 2022, has no active business operations. The entity originated as Sparrow Ventures Corp. (IPO 2008), was later renamed Westcot Ventures Corp., and in December 2019 completed a reverse takeover of WPD Pharmaceuticals Sp. z o.o., a Poland-based biotechnology R&D company focused on oncology drug development. Following a November 2022 restructuring, WPD Pharmaceuticals Inc. lost control of the Polish subsidiary and now retains only an approximately 7% equity stake; the Polish entity continues to develop drug candidates including Berubicin (recurrent glioblastoma multiforme, Phase 1B/2), Annamycin in liposomal form (acute myeloid leukemia and soft tissue sarcoma lung metastases, Phase 1B/2), WP1066 (STAT3 inhibitor, FDA IND-approved in pediatric brain cancer), and WP1122 (glycolysis inhibition, including SARS-CoV-2 work), all licensed from Wake Forest University Health Sciences. Historical revenue mechanics centered on licensing royalties and government grant funding (notably ~C$7.4M for Berubicin, ~C$6.7M for Annamycin, and ~US$6.3M for liposomal Annamycin AML development), with cumulative drug-development spend exceeding US$100M as of February 2020; the parent entity itself currently generates no revenue.

WPD Pharmaceuticals firmographics

Firmographics
Name
WPD Pharmaceuticals
Legal name
WPD Pharmaceuticals Inc.
Website
https://wpdpharmaceuticals.com
Company type
Public
Founded year
2008
Operating status
Operating
Headcount range
11–50 employees
Short description
WPD Pharmaceuticals Inc. (CSE: WBIO, FSE: 8SV1) is a publicly traded Canadian holding company with no active operations, holding approximately 7% of its former Polish oncology R&D subsidiary, WPD Pharmaceuticals Sp. z o.o.
Ownership category
akta.pro rank

WPD Pharmaceuticals industry classification

Industry
Product category
Oncology Pharmaceuticals
NAICS
Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAIACAI
Hematology Specialty Pharmaceuticals (Non-malignant)
SECONDARYHLAIACAD
Endocrinology & Metabolic Specialty Pharmaceuticals

Keywords

  • Oncology drug development
  • Biopharmaceutical research
  • Clinical trials oncology
  • Small molecule therapeutics
  • Biologics development

Where WPD Pharmaceuticals is headquartered

Location

Headquarters

HQ city
Warsaw
HQ country
Poland
HQ region
Europe

Offices2 records

Markets served

WPD Pharmaceuticals business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Revenue model

  1. Licensing Royalties: The company generates no active revenue currently. WPD Pharmaceuticals Inc. (CSE: WBIO) has no active business operations. The company's sole asset is shares (approximately 7%) in its former subsidiary WPD Pharmaceuticals Sp. z o.o., a biotechnology R&D company in Poland that focuses on oncology drug development.
  2. Grant Funding: The company has historically received government grants for drug development including C$7.4 million grant for Berubicin development and $6.3M grant for liposomal Annamycin development for AML treatment.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

WPD Pharmaceuticals product offering

Product offering

Core offering

WPD Pharmaceuticals Inc. is a publicly traded biotechnology company focused on oncology research and development of medicinal products involving biological compounds and small molecules. Its pipeline includes licensed drug candidates such as Berubicin (for recurrent glioblastoma multiforme), Annamycin (for AML and soft tissue sarcoma lung metastases), WP1066 (a STAT3 inhibitor), and WP1122 (a glycolysis inhibitor). The company currently has no active business operations and holds approximately 7% of its former Polish subsidiary, WPD Pharmaceuticals Sp. z o.o.

Differentiator

Problem solved

Functional benefit

Quantifiable outcome

  • Phase 1B/2 clinical trials ongoing for Berubicin in recurrent glioblastoma multiforme
  • +4 more outcomes

Companies that use WPD Pharmaceuticals

Customer profile

Segments2 records

Ideal customer profiles2 records

WPD Pharmaceuticals technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

WPD Pharmaceuticals partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and minor.

  • Wake Forest University Health SciencescoreStrategic or Co-development Partner · 16 May 2022WPD Pharmaceuticals signed an annex to its license agreement with Wake Forest University Health Sciences in May 2022. The company holds exclusive sublicense rights for Berubicin, Annamycin, WP1066, and WP1122 drug candidates. Berubicin sublicense rights were secured in perpetuity in February 2022.
  • EuroNanoMedminorStrategic or Co-development Partner · 7 March 2022WPD Pharmaceuticals signed a consortium agreement with EuroNanoMed in March 2022 as part of an international research consortium.
  • Moleculin BiotechcoreStrategic or Co-development Partner · 30 March 2021WPD Pharmaceuticals entered into an amended and restated sublicense agreement with Moleculin Biotech in January 2022, following an initial agreement in March 2021. The agreement covers WP1066, WP1122, and Annamycin drug candidates.
  • ClinigenminorImplementation/ SI/ Consulting Partner · 14 January 2021WPD Pharmaceuticals contracted Clinigen Clinical Supplies Management to perform QP (Qualified Person) certification of Berubicin for clinical trial authorization.
  • Worldwide Clinical TrialscoreImplementation/ SI/ Consulting Partner · 9 September 2020WPD Pharmaceuticals engaged Worldwide Clinical Trials as a CRO (Contract Research Organization) for Phase 2 Berubicin trials in September 2020, with additional support engaged in February 2021.
  • CNS PharmaceuticalscoreStrategic or Co-development Partner · 24 March 2020WPD Pharmaceuticals partnered with CNS Pharmaceuticals on drug development, including clinical trials for Berubicin in Poland. The companies identified leading Polish medical institutions for Berubicin Phase 2 clinical trial and received positive opinion from the Polish Central Ethics Committee.

Scale indicators6 records

Recent moves9 records

Expansion highlights4 records

WPD Pharmaceuticals competitors and assessment

Company assessment

Direct peers

  • Moleculin Biotech: Co-development partner on Annamycin, WP1066, and WP1122 via amended and restated sublicense agreement. Highly comparable as a small-cap oncology biotech advancing the same drug candidates that originally underpinned WPD's pipeline.
  • CNS Pharmaceuticals: Partner advancing Berubicin Phase 1B/2 trials for recurrent glioblastoma multiforme, with Polish clinical sites jointly identified. Directly comparable as a small-cap oncology biotech focused on the same lead asset.
  • Kazia Therapeutics: Small-cap oncology biotech with lead asset paxalisib in glioblastoma. Comparable therapeutic focus (GBM, high unmet need) and similar company stage/size profile to the operating business previously housed in WPD's subsidiary.
  • TuHURA Biosciences: Formed via merger with Kintara Therapeutics; focused on novel approaches to glioblastoma and other cancers. Comparable as a micro-cap oncology biotech targeting similar indications with similar regulatory/clinical risk profile.
  • Mustang Bio: Clinical-stage biopharma developing cell and gene therapies for oncology and rare diseases. Comparable as a small-cap public biotech with limited operating cash flow and ongoing capital-raising needs.
  • Cardiff Oncology: Clinical-stage oncology biotech developing therapeutics for KRAS-mutated cancers. Comparable in size, stage, and public small-cap oncology profile to the type of business historically operated by WPD's Polish subsidiary.
  • Aprea Therapeutics: Clinical-stage biopharma developing novel oncology therapeutics targeting the p53 pathway. Comparable as a small-cap public oncology biotech with similar cash burn and dependency on clinical milestones for valuation.

Regional players

  • InMed Pharmaceuticals: Canada-based clinical-stage biopharmaceutical company developing small-molecule drug candidates. Comparable as a domestic (Canadian) small-cap biotech with similar listing profile and life-sciences focus.

Broad incumbents

  • Roche: Global pharmaceutical incumbent with extensive oncology franchise including GBM treatments. Relevant as a broad incumbent that competes for the same oncology indications WPD's former subsidiary targets and that could potentially acquire/license comparable assets.
  • Bristol-Myers Squibb: Large-cap global pharma with a deep oncology and hematology portfolio. Provides broad incumbent context for the oncology indications WPD's former subsidiary was pursuing, and represents a plausible strategic acquirer profile.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

WPD Pharmaceuticals social profiles

Digital presence

WPD Pharmaceuticals financial estimates

Financial estimate

Revenue estimate

Valuation estimate

WPD Pharmaceuticals leadership team

Management profile

Number of profiles

Profiles8 records

WPD Pharmaceuticals subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

WPD Pharmaceuticals funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

WPD Pharmaceuticals M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about WPD Pharmaceuticals

What does WPD Pharmaceuticals do?

WPD Pharmaceuticals Inc. is a publicly traded biotechnology company focused on oncology research and development of medicinal products involving biological compounds and small molecules. Its pipeline includes licensed drug candidates such as Berubicin (for recurrent glioblastoma multiforme), Annamycin (for AML and soft tissue sarcoma lung metastases), WP1066 (a STAT3 inhibitor), and WP1122 (a glycolysis inhibitor). The company currently has no active business operations and holds approximately 7% of its former Polish subsidiary, WPD Pharmaceuticals Sp. z o.o.

Is WPD Pharmaceuticals a public or private company?

WPD Pharmaceuticals is a public company. It is classified as public and is currently operating.

When was WPD Pharmaceuticals founded?

WPD Pharmaceuticals was founded in 2008. It employs 11 to 50 people.

Where is WPD Pharmaceuticals based?

WPD Pharmaceuticals is headquartered in Warsaw, Poland, in the Europe region.

How does WPD Pharmaceuticals make money?

Two revenue lines are on record. Licensing Royalties are the primary driver. The others are grant Funding.

Who are WPD Pharmaceuticals's main competitors?

Direct peers on record are Moleculin Biotech, CNS Pharmaceuticals, Kazia Therapeutics, TuHURA Biosciences, Mustang Bio, Cardiff Oncology and Aprea Therapeutics. InMed Pharmaceuticals is listed as a regional player. Broad incumbents are Roche and Bristol-Myers Squibb.

Does WPD Pharmaceuticals have an API?

No public API is recorded for WPD Pharmaceuticals.

What industry is WPD Pharmaceuticals in?

WPD Pharmaceuticals's product category is Oncology Pharmaceuticals. Its primary akta.pro industry code is HLAIACAI, Hematology Specialty Pharmaceuticals (Non-malignant), with a secondary code of HLAIACAD, Endocrinology & Metabolic Specialty Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PRLogWPD Pharmaceuticals Provides A Corporate UpdateWPD Pharmaceuticals provided a corporate update, authorizing Houston Pharmaceuticals to subscribe for 34,000 shares of its Polish subsidiary at PLN 50 each for gross proceeds of PLN 1,700,000. Houston would own 80.95% of WPD Poland after registration, with the financing serving as a bridge until additional capital is raised. The company expects to file its annual financial statements by November 30, 2022.GlobeNewswireWPD Pharmaceuticals Signs Annex to License Agreement with Wake Forest University Health SciencesWPD Pharmaceuticals signed Annex No. 2 to its license agreement with Wake Forest University Health Sciences, expanding the licensed know-how scope. The annex covers patent rights including US 11,136,367 and related applications, and the company expects the data could lead to significant pipeline developments.GlobeNewswireWPD Pharmaceuticals Signs Consortium Agreement on EuroNanoMed ProjectWPD Pharmaceuticals signed a consortium agreement for the EuroNanoMed project, which will research AGuIX nanoparticles to improve radiotherapy for brain tumors. The three-year project, funded by EuroNanoMed III, will test two of WPD's compounds to restore glioblastoma cells' sensitivity to radiotherapy. The consortium includes Oslo University Hospital, NH TherAguix, and Jagiellonian University.GlobeNewswireWPD Pharmaceuticals Announces Appointment of New DirectorWPD Pharmaceuticals appointed Romuald Harwas as director effective February 2, 2022, filling the vacancy left by Walter Klemp's resignation. Harwas brings finance experience from roles including CFO and board member. CEO Mariusz Olejniczak said his life science expertise will be valuable as the company advances its drug portfolio.GlobeNewswireWPD Pharmaceuticals Secures Berubicin Sub-License Rights in PerpetuityWPD Pharmaceuticals secured perpetual sublicense rights to Berubicin from CNS Pharmaceuticals after CNS confirmed the company spent at least $2 million on development. The sublicense grants geographic exclusivity for development and marketing in select Eastern European and Central Asian countries.GlobeNewswireWPD Pharmaceuticals Enters into Amended and Restated Sublicense Agreement with Moleculin BiotechWPD Pharmaceuticals entered an amended sublicense agreement with Moleculin Biotech, raising minimum commercial development spending to $13 million over five years. The deal also includes a consent for LPC Enterprises to assume WPD Poland's rights under a convertible note with a $8 million valuation cap.GlobeNewswireWPD Pharmaceuticals Invited to Join International Research ConsortiumWPD Pharmaceuticals was invited to join an international consortium researching AGuIX nanoparticles to enhance radiotherapy for brain tumors. The consortium will study WPD's compounds WP1066 and WP1122 to restore glioblastoma cells' sensitivity to radiotherapy. The three-year project, funded by EuroNanoMed III, aims to optimize X-ray doses while preserving healthy tissue.GlobeNewswireWPD Pharmaceuticals Announces Berubicin Supply Agreement for the Upcoming Clinical TrialsWPD Pharmaceuticals signed an agreement with CNS Pharmaceuticals to obtain Berubicin investigational medicinal product for planned clinical trials. WPD will purchase half of a batch previously manufactured for CNS, with trials planned to begin in the first half of 2021. The company hopes to receive regulatory approval within three months of submission.GlobeNewswireWPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 StudyWPD Pharmaceuticals and CNS Pharmaceuticals announced positive ethics committee approval for WPD-201 and Central IRB approval for CNS-201, both for Berubicin trials in glioblastoma. WPD plans to initiate a Phase 2 adult GBM trial in H1 2021 and a pediatric Phase 1 trial in 2021, with CNS planning its Phase 2 trial in Q1 2021.PR NewswireWPD and CNS Pharmaceuticals Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 StudyWPD Pharmaceuticals received a positive opinion from the Lower Silesian Medical Chamber Ethics Committee in Poland for its planned Berubicin clinical trial protocol (WPD-201) in adults with Glioblastoma Multiforme, while CNS Pharmaceuticals received Central IRB study level approval for its CNS-201 protocol. WPD plans to submit its application to the Polish Office for Registration of Medicinal Products, Medical Devices and Biocidal Products, aiming to begin patient recruitment within three months of approval. The companies, operating under a 2019 sublicense agreement, are advancing Berubicin through multiple clinical trials in 2021, with WPD's program partially funded by a $6 million reimbursement grant from the Polish National Center for Research and Development.